Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.45 |
| ▸ | PPARA | Q07869 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.42 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8233122 | 0.94 | CYP2C19 (0.45) | PPARGPPARAGAAHTTCYP2C19 | |
| SCHEMBL8233844 | 0.85 | MMP8 (0.55) | PPARGPPARACYP2C19MMP8RAB9A | |
| SCHEMBL13696274 | 0.83 | CYP2C19 (0.46) | PPARGPPARACYP2C19PPARDRAB9A | |
| SCHEMBL8231003 | 0.82 | HTT (0.43) | PPARGPPARAGAAHTTCYP2C19 | |
| SCHEMBL8233123 | 0.81 | CYP2C19 (0.45) | PPARGPPARACYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL4098653 | 0.81 | PPARG (0.40) | PPARGPPARAHTTCYP2C19PPARD | |
| SCHEMBL15161546 | 0.79 | GAA (0.41) | PPARGPPARAGAAHTTCYP2C19 | |
| SCHEMBL13696272 | 0.79 | CYP2C19 (0.49) | PPARGPPARAGAAHTTCYP2C19 | |
| SCHEMBL9691089 | 0.79 | MMP8 (0.56) | PPARGPPARACYP2C19CTRB1KCNN4 | |
| SCHEMBL4098649 | 0.79 | MMP8 (0.57) | PPARGPPARACYP2C19MMP8RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221640-A1 | Novel Crystal Modifications | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| WO-2007106022-A2 | A NEW CRYSTALLINE FORM G OF (5S) -5- [4- (5-CHLORO-PYRIDIN-2- YLOXY) -PIPERIDINE-1-SULFONYLMETHYL] - 5 -METHYL -IMIDAZOLIDINE - 2,4-DIONE (I) AND INTERMEDIATES THEREOF. | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221640-A1 | Novel Crystal Modifications | PTMS, NT5C, CDK5 | PPARG 1184/4885PPARA 1009/4885GAA 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.